Hello, everyone. Nice to see you again. We hope you had a pleasant respite and feel refreshed after the holiday break. Now, of course, the time has come to resume the routine, which means gearing up for those meetings and deadlines. As always, we have gathered a few items to help you along. Meanwhile, please join us for a much-needed cup of stimulation. Hope your day goes well...
Inspire Pharma's Cystic Fibrosis Drug Fails (Reuters)
Elder Pharma Gets Japanese Approval For API Facility (Business Standard)
J&J And MassGen Strike Deal For Testing Cancer Cells (Boston Globe)
UK's NICE May Back Avastin For Macular Degeneration (The Guardian)
Roche Buys Marcadia And Its Obesity Compounds (BioWorld Today)
Indian Pharmas Had Most ANDA Approvals (Business Standard)
AstraZeneca's Brennan Ponders The Future (Bloomberg News)
Australian Regulator Fails To Track Pharma Gifts (Sydney Morning Herald)
Pfizer Ordered To Pay $1.5M In Prempro Damages (Bloomberg News)
Cipla Charged With Overpricing (Hindu Business Line)
US Trustee Says Pfizer Quigley Unit Bankruptcy Should End (Bloomberg News)
Warburg Pincus Pays $227M For ReSearch Pharma (Genetic Engineering News)
Pfizer Buys Veterinary Diagnostics Company (Dow Jones)
Pfizer Buys Strides-Akorn Portfolio (Business Standard)
Factory Explosion Kills Five In China (Global Times)
Pfizer Trovan Settlement Spawns Controversy In Nigeria (AllAfrica)